Amgen, founded in 1980, has been a cornerstone of the biotechnology and pharmaceutical industries. Known for its slogan #WeareBiotech, the company leverages biology and technology to combat severe diseases, striving to enhance and extend human lives. Amgen's commitment to research and development has facilitated a robust pipeline that supplements its existing portfolio targeting cancer, heart disease, osteoporosis, and both inflammatory and rare diseases.
As a distinguished member of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen's innovative prowess was recognized in 2024 as one of the "World’s Most Innovative Companies" by Fast Company and one of "America’s Best Large Employers" by Forbes. Headquartered in the United States, Amgen's last notable financial activity includes a substantial $4.00 billion post-IPO debt investment, strengthening its strategic positioning within the market. Amgen continues to be a substantial player in the health care sector, with a reputation supported by its extensive history and recent financial growth.